Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study

J Inherit Metab Dis. 2014 Nov;37(6):961-8. doi: 10.1007/s10545-014-9693-8. Epub 2014 Mar 18.

Abstract

Objectives: To determine the effectiveness of enzyme replacement therapies (ERT) for children with Gaucher disease (GD).

Design: A longitudinal cohort study including prospective and retrospective clinical data. Age- and gender-adjusted treatment effects were estimated using generalised linear mixed models. Children on treatment contributed data before and during treatment. Children not on treatment contributed natural history data.

Participants: Consenting children (N = 25, aged 1.1 to 15.6 years) with a diagnosis of GD (14 with GD1 and 11 with GD3) who attended a specialist treatment centre in England. At recruitment, 24 patients were receiving ERT (mean treatment duration, 5.57 years; range 0-13.7 years).

Outcome measures: Clinical outcomes chosen to reflect disease progression, included platelet count; haemoglobin and absence/presence of bone pain.

Results: Duration of ERT was associated with statistically significant improvements in platelet count (p < 0.001), haemoglobin (p < 0.001), and reported bone pain (p = 0.02). The magnitude of effect on haematological parameters was greater in children with GD3 than in those with GD1.

Conclusions: These data provide further evidence of the long-term effectiveness of ERT in children with GD.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Disease Progression
  • England
  • Enzyme Replacement Therapy / methods*
  • Female
  • Gaucher Disease / complications
  • Gaucher Disease / drug therapy*
  • Glucosylceramidase / therapeutic use*
  • Hemoglobins / analysis
  • Humans
  • Infant
  • Longitudinal Studies
  • Male
  • Platelet Count
  • Prospective Studies
  • Regression Analysis
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Hemoglobins
  • Glucosylceramidase